Sanofi India Limited

SANOFI.BO

Drug Manufacturers - General · Healthcare

Price

₹3345.50

-5.65 (-0.17%)

Market Cap

₹77.08B

Exchange

Bombay Stock Exchange

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 9, 2026 · filings through Jun 30, 2026

Sanofi India Limited is the Indian subsidiary of Sanofi, a large French pharmaceutical company. It makes and sells prescription medicines, vaccines, and consumer healthcare products in India, serving patients, hospitals, doctors, and pharmacies across the country. The company focuses on areas like diabetes, cardiovascular disease, and specialty care.

Sanofi India earns money by selling its medicines and healthcare products directly to the Indian market, with revenue coming from both branded prescription drugs and over-the-counter products. It operates primarily within India and benefits from the strong brand recognition and research pipeline of its French parent company, which gives it access to globally developed drugs. The key growth driver is India's expanding middle class and rising demand for quality healthcare, but the company faces risk from government price controls on medicines, which can limit how much it can charge for its products.

Winston Score History

Share count broadly stable

+0.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 23.0M (2021) → 23.0M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

48.5%

Healthy — 48.5% gross margin

Operating Margin

24.3%

Excellent — 24.3% operating margin

ROCE

12.9%

Good — 12.9% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-5.8%

Shrinking sales (-5.8% YoY)

EPS YoY

-4.1%

Earnings shrinking (-4.1% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

45%

Weak — only 45% of profit becomes cash

FCF Margin

7.7%

Modest free cash flow (7.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

278.81x

Comfortably covers interest (278.8x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

23.8x

Growth-priced — P/E 23.8

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

+5.0

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (23.8 → 18.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

3.71%

Moderate income — 3.71% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth

-67.8%

Dividend cut (-67.8% YoY) — warning sign

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial